- Tytuł:
- Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial
- Autorzy:
- Źródło:
- In The Lancet Oncology June 2022 23(6):818-828
Czasopismo naukowe